Virios TherapeuticsVIRI
Market Cap: 6.11M
About: Virios Therapeutics Inc is a development-stage biotechnology company. It is focused advancing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response, such as fibromyalgia ("FM") and Long-COVID ("LC"). Its product candidates includes IMC-1 and IMC-2, IMC-1, is intended to synergistically suppress herpesvirus activation and replication with a more specific activity against the Epstein-Barr virus (herpesvirus HHV-4, IMC-2 is a combination of valacyclovir and celecoxib.
Employees: 4
Fund manager confidence
Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)
200% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 1
0% more funds holding
Funds holding: 20 [Q4 2023] → 20 (+0) [Q1 2024]
0% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 5
0.95% less ownership
Funds ownership: 4.47% [Q4 2023] → 3.52% (-0.95%) [Q1 2024]
34% less capital invested
Capital invested by funds: $493K [Q4 2023] → $325K (-$169K) [Q1 2024]
Research analyst outlook
1 Wall Street Analyst provided 1 year price forecasts over the past 6 months
1 analyst rating
Maxim Group Jason McCarthy | 355%upside $1 | Buy Initiated | 20 Jun 2024 |